Genentech

BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...

SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...

SOUTH SAN FRANCISCO, Calif., May 31, 2026 Genentech, a member of the Roche Group, announced that new clinical data...

SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...

South San Francisco, California, USA – April 21, 2026 In a major breakthrough for rare neurological diseases, Genentech has...

SOUTH SAN FRANCISCO, California – March 6, 2026 Genentech announced positive topline results from the Phase II ZUPREME-1 clinical...

NEW YORK, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by...

DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...